GlassScriptPhysician profile
Michael V Greenwell
NPI 1104821735
$8,256.40
in general payments reported to CMS, 2019-2025
35 companies · $1,743 in 2025
The $1,743 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,516 · 2020: $566 · 2021: $321 · 2022: $1,149 · 2023: $1,384 · 2024: $1,577 · 2025: $1,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,684 · Education: $19.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,684.09 |
| Education | $19.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,111.28 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,316.63 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $795.63 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $722.61 | 2019-2025 | Tremfya, Stelara |
| Genzyme Corporation | $398.10 | 2022-2025 | |
| Gilead Sciences, INC. | $279.78 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $222.09 | 2019-2024 | Rebyota, Clenpiq |
| Braintree Laboratories, INC. | $190.00 | 2019-2025 | Suflave |
| Phathom Pharmaceuticals, INC. | $177.97 | 2024-2025 | Voquezna |
| Pfizer INC. | $177.09 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $171.93 | 2019-2024 | Ocaliva |
| Merck Sharp & Dohme LLC | $167.61 | 2019-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $158.36 | 2020-2025 | Linzess |
| Celgene Corporation | $157.90 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $147.35 | 2022-2025 | Dupixent |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $142.37 | 2024-2025 | Rezdiffra, Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $119.70 | 2023 | Zeposia |
| Ardelyx, INC. | $115.84 | 2023-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $103.21 | 2022-2023 | |
| Shionogi INC | $76.21 | 2019 | |
| Organon LLC | $72.31 | 2023-2025 | Renflexis, Hadlima |
| Amgen INC. | $71.38 | 2023 | Amjevita, Avsola |
| Exact Sciences Corporation | $59.00 | 2023-2025 | Cologuard Collection Kit |
| Csl Behring | $38.27 | 2019 | |
| Lilly USA, LLC | $37.83 | 2024-2025 | Omvoh |
| Shire North American Group INC | $35.02 | 2019 | |
| Redhill Biopharma INC. | $34.89 | 2022-2023 | Talicia, Movantik, Aemcolo |
| Sandoz INC. | $33.17 | 2025 | Hyrimoz |
| Evoke Pharma, INC. | $25.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.72 | 2025 | |
| Aimmune Therapeutics, INC. | $17.41 | 2024 | |
| Romark Laboratories, Lc | $16.89 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.64 | 2023 | Cyltezo |
| Ipsen Biopharmaceuticals, INC | $14.30 | 2025 | Iqirvo |
| Alfasigma USA, INC. | $13.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Greenwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.